Liver contrast enhanced ultrasound perfusion imaging in the evaluation of chronic hepatitis C fibrosis: Preliminary results

Ultrasound in Medicine and Biology

Volumn 37, Issue 1, 2011, Pages 1-6

  Orlacchio, Antonio ^a   Bolacchi, Francesca ^a   Petrella, Maria Chiara ^a   Pastorelli, Daniela ^a   Bazzocchi, Gabriele ^a   Angelico, Mario ^a   Simonetti, Giovanni ^a  

^a TOR VERGATA UNIVERSITY HOSPITAL   (Italy)

Author keywords

Chronic hepatitis C; Contrast enhanced ultrasound; Liver fibrosis; Perfusion imaging

Indexed keywords

CHARACTERISTIC CURVE; CHRONIC HEPATITIS; COMPLEMENTARY TOOLS; CONTRAST ENHANCED ULTRASOUND; CONTROL SUBJECT; DIAGNOSTIC ACCURACY; LIVER FIBROSIS; LIVER LOBE; MILAN , ITALY; NETHERLANDS; PEAK SIGNAL INTENSITIES; PERFUSION IMAGING; PHILIPS; PORTAL VEINS; REGIONS OF INTEREST; STATISTICALLY SIGNIFICANT DIFFERENCE; TRANSVERSE SECTION; ULTRASOUND SYSTEM; WIDE-BAND;

COMPUTERIZED TOMOGRAPHY; ULTRASONIC IMAGING; ULTRASONICS; ULTRASONOGRAPHY;

LIVER;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTRAST ENHANCEMENT; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC IMAGING; DISEASE SEVERITY; ECHOGRAPHY; FEMALE; HEPATITIS C; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; LIVER BLOOD FLOW; LIVER FIBROSIS; LIVER PARENCHYMA; LIVER SCINTISCANNING; MALE; PORTAL VEIN; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY;

AGED; BIOPSY; CASE-CONTROL STUDIES; CONTRAST MEDIA; FEMALE; HEPATITIS C, CHRONIC; HUMANS; IMAGE INTERPRETATION, COMPUTER-ASSISTED; LIVER CIRRHOSIS; MALE; MIDDLE AGED; PHOSPHOLIPIDS; PROSPECTIVE STUDIES; ROC CURVE; SENSITIVITY AND SPECIFICITY; STATISTICS, NONPARAMETRIC; SULFUR HEXAFLUORIDE;

EID: 78649963276     PISSN: 03015629     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ultrasmedbio.2010.10.012     Document Type: Article

References (23)

1. Albrecht T., Blomley M.J., Cosgrove D.O., Taylor-Robinson S.D., Jayaram V., Eckersley R., Urbank A., Butler-Barnes J., Patel N. Non-invasive diagnosis of hepatic cirrhosis by transit-time analysis of an ultrasound contrast agent. Lancet 1999, 353:1579-1583.
2. Blomley M.J., Lim A.K., Harvey C.J., Patel N., Eckersley R.J., Basilico R., Heckemann R., Urbank A., Cosgrove D.O., Taylor-Robinson S.D. Liver microbubble transit time compared with histology and Child-Pugh score in diffuse liver disease: A cross sectional study. Gut 2003, 52:1188-1193.
3. Cadranel J.F., Rufat P., Degos F. Practices of liver biopsy in France: Results of a prospective nationwide survey. For the Group of Epidemiology of the French Association for the Study of the Liver (AFEF). Hepatology 2000, 32:477-481.
4. Fowell A.J., Iredale J.P. Emerging therapies for liver fibrosis. Dig Dis 2006, 24:174-183.
5. Goodman Z.D. Grading and staging systems for inflammation and fibrosis in chronic liver diseases. J Hepatol 2007, 47:598-607.
6. Harrer J.U., Klotzsch C., Stracke C.P., Möller-Hartmann W. Cerebral perfusion sonography in comparison with perfusion MRT: A study with healthy volunteers. Ultraschall Med 2004, 25:263-269.
7. Hirata M., Akbar S.M., Horiike N., Onji M. Noninvasive diagnosis of the degree of hepatic fibrosis using ultrasonography in patients with chronic liver disease due to hepatitis C virus. Eur J Clin Invest 2001, 31:528-535.
8. Kaneko T., Teshigawara O., Sugimoto H., Hirota M., Inoue S., Takeda S., Nakao A. Signal intensity of the liver parenchyma in microbubble contrast agent in the late liver phase reflects advanced fibrosis of the liver. Liver Int 2005, 25:288-293.
9. Kono Y., Steinbach G.C., Peterson T., Schmid-Schönbein G.W., Mattrey R.F. Mechanism of parenchymal enhancement of the liver with a microbubble-based US contrast medium: An intravital microscopy study in rats. Radiology 2002, 224:253-257.
10. Krix M. Quantification of enhancement in contrast ultrasound: A tool for monitoring of therapies in liver metastases. Eur Radiol 2005, 15:104-108.
11. Leen E., Angerson W.J., Yarmenitis S., Bongartz G., Blomley M., Del Maschio A., Summaria V., Maresca G., Pezzoli C., Llull J.B. Multi-centre clinical study evaluating the efficacy of SonoVue (BR1), a new ultrasound contrast agent in Doppler investigation of focal hepatic lesions. Eur J Radiol 2002, 41:200-206.
12. Leen E., Ceccotti P., Kalogeropoulou C., Angerson W.J., Moug S.J., Horgan P.G. Prospective multicenter trial evaluating a novel method of characterizing focal liver lesions using contrast-enhanced sonography. AJR Am J Roentgenol 2006, 186:1551-1559.
13. Li J., Dong B.W., Yu X.L., Li C.F. Gray scale contrast enhancement and quantification in different positions of rabbit liver. J Ultrasound Med 2006, 25:7-14.
14. Lim A.K., Taylor-Robinson S.D., Patel N., Eckersley R.J., Goldin R.D., Hamilton G., Foster G.R., Thomas H.C., Cosgrove D.O., Blomley M.J. Hepatic vein transit times using a microbubble agent can predict disease severity non-invasively in patients with hepatitis C. Gut 2005, 54:128-133.
15. Meves S.H., Wilkening W., Thies T., Eyding J., Hölscher T., Finger M., Schmid G., Ermert H., Postert T. Ruhr Center of Competence for Medical Engineering. Comparison between echo contrast agent-specific imaging modes and perfusion-weighted magnetic resonance imaging for the assessment of brain perfusion. Stroke 2002, 33:2433-2437.
16. Pedersen J.F., Larsen V.A., Bytzer P., Madsen L.G., Hamberg O. Hepatic transit time of ultrasound contrast in biopsy characterized liver disease. Acta Radiol 2005, 46:557-560.
17. Ridolfi F., Abbattista T., Marini F., Vedovelli A., Quagliarini P., Busilacchi P., Brunelli E. Contrast-enhanced ultrasound to evaluate the severity of chronic hepatitis C. Dig Liver Dis 2007, 39:929-935.
18. Rockey D. Hepatic blood flow regulation by stellate cells in normal and injured liver. Semin Liver Dis 2001, 21:337-350.
19. Sebastiani G., Vario A., Guido M., Alberti A. Performance of noninvasive markers for liver fibrosis is reduced in chronic hepatitis C with normal transaminases. J Viral Hepat 2008, 15:212-218.
20. Searle J., Mendelson R., Zelesco M., Sanford J., Cheng W., McKinstry C., Ramsay D. Non-invasive prediction of the degree of liver fibrosis in patients with hepatitis C using an ultrasound contrast agent. A pilot study. J Med Imaging Radiat Oncol 2008, 52:130-133.
21. Staub F., Tournoux-Facon C., Roumy J., Chaigneau C., Morichaut-Beauchant M., Levillain P., Prevost C., Aubé C., Lebigot J., Oberti F., Galtier J.B., Laumonier H., Trillaud H., Bernard P.H., Blanc J.F., Sironneau S, Machet F, Drouillard J., de Ledinghen V, Couzigou P, Foucher P, Castéra L, Tranquard F, Bacq Y., d'Altéroche L., Ingrand P., Tasu J.P. Liver fibrosis staging with contrast-enhanced ultrasonography: Prospective multicenter study compared with METAVIR scoring. Eur Radiol 2009, 19:824-829.
22. Weber M.A., Krix W., Delorme S. Quantitative evaluation of muscle perfusion with CEUS and with MR. Eur Radiol 2007, 17:2663-2674.
23. Zhang Y., Cao T.S. Grey scale enhancement by a new self-made contrast agent in early cirrhotic stage of rabbit liver. BMC Gastroenterol 2007, 8:7-32.